Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy-Reference-Cited by-同舟云学术

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy

Published:2000-07-01 Issue:1 Volume:106 Page:117-124
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Fehniger Todd A.,Bluman Eric M.,Porter Michelle M.,Mrózek Ewa,Cooper Megan A.,VanDeusen Jeffrey B.,Frankel Stanley R.,Stock Wendy,Caligiuri Michael A.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference30 articles.

1. Biology of Natural Killer Cells

2. Biology and clinical relevance of human natural killer cells

3. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.

4. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo.

5. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging‐Based Efficacy Evaluation of Cancer Immunotherapy in Engineered Tumor Platforms and Tumor Organoids;Advanced Healthcare Materials;2024-06-08

2. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression;Frontiers in Immunology;2024-04-18

3. A Smart Responsive Nanotheranostic System for MRI of Tumor Response to Immunotherapy and Enhanced Synergism of Thermo‐Immunotherapy;Advanced Functional Materials;2024-01-20

4. Natural Killer Cell-Derived Extracellular Vesicles as a Promising Immunotherapeutic Strategy for Cancer: A Systematic Review;International Journal of Molecular Sciences;2023-02-16

5. Molecular remission using personalized low-dose immunotherapy with minimal toxicities for poor prognosis hematological and solid tumor cancers;NK Cells in Cancer Immunotherapy: Successes and Challenges;2023